glp 1 agonists oral new agonist In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron The Impact of GLP-1 Receptor
Description
95 ( n = 224) included a cohort with more severe disease with 17% of patients affected by perianal involvement and 24% classified as having penetrating or fistulizing disease
We decided to pursue "Mission Impossible": the most sophisticated, longevity-friendly GLP-1 design imaginable
2,4 GLP-1 increases insulin secretion, decreases glucagon release, slows gastric emptying and reduces food intake
Nausea, diarrhea, and vomiting were the most common complaints, occurring primarily during dose escalation periods
Zhang Q, et al
